Table 4. Transplant outcome for PHANTASTIC and control patients.
| PHANTASTIC | Controls | ||
|---|---|---|---|
| Have undergone BMT | 85 (87) | 119 (80) | |
| After 1 round of harvesting | 79 (81) | 100 (67) | |
| After 2 rounds of harvesting | 1 | 16 | |
| After 3 rounds of harvesting | 2 | 1 | |
| Received allograft | |||
| Due to disease concerns | 3 | — | |
| After failing 2 harvesting rounds | — | 2 | |
| Reason for no BMT | |||
| Disease progression | 9 (9) | 12 (8) | |
| Insufficient cells | 1a (1) | 4a (3) | |
| Deemed unfit for BMT | 1 (1) | 8 (5) | |
| Personal reasons | 2 (2) | 5 (3) | |
| Unknown | — | 1 (1) | |
| Median engraftment times | |||
| Days to neutrophils to 0.5 × 109/l | 12 | 11 | P<0.001 |
| Days to platelets to 50 × 109/l | 20 | 18 | P<0.001 |
| Outcome at 12 months post harvesting | |||
| Total assessable cases | 86 | 148 | |
| Alive and well | 67 (78) | 114 (77) | |
| Relapsed | 18 (21) | 29 (20) | |
| Died other than relapse | 1 (1) | 5 (3) | |
Figures in parentheses are percentages. Significance testing is by Mann–Whitney comparison. Engraftment day is defined as the first of 2 consecutive days post transplant at which the specified neutrophil or platelet counts are achieved.
a
Insufficient cells after two rounds of harvesting.